Table 3.
Effect of glibenclamide and MSLA on the lipid profile of alloxan-induced diabetic rats
| Group | Treatment | Total cholesterol (mg/dl) |
Teriglycerides (mg/dl) |
LDL (mg/dl) | HDL (mg/dl) |
|---|---|---|---|---|---|
| 1. | Normal saline (10 mL/kg) | 63.75±5.54 | 50.00±6.89 | 47.90±4.43 | 48.00±2.87 |
| 2. | Diabetic control (150 mg/kg) | 180.66±5.54# | 155.00±15.56# | 105.66±9.13# | 44.00±7.37 |
| 3. | Glibenclamide (2 mg/kg) | 75.5±2.23* | 81.83±7.19* | 17.46±3.97* | 41.66±2.99 |
| 4. | MSLA (300 mg/kg) | 95.66±4.75*a | 89.83±5.26* | 26.20±5.10* | 51.50±3.58a |
Data are mean ± SEM, n=24. One-way ANOVA+Tukey test against hypercholesterolemic rats
#
P<0.0001 Diabetic control rats were compared with normal control rats.
*
P<0.0001 Diabetic treated rats were compared with diabetic control rats.
a
P<0.05 Diabetic treated rats with MSLA were compared with Diabetic treated rats with glinenclamide.